Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.30 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43231 | 0.86 | HPGD (0.36) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL20091594 | 0.84 | HPGD (0.33) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL20968654 | 0.79 | — | — | |
| SCHEMBL8735537 | 0.79 | HPGD (0.37) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL13001926 | 0.78 | HPGD (0.33) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL24045358 | 0.77 | HPGD (0.31) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL3705350 | 0.76 | HDAC3 (0.44) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL16072747 | 0.76 | HPGD (0.43) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL15426045 | 0.76 | MEN1 (0.40) | HPGDHTTSMN1; SMN2 | |
| SCHEMBL16453924 | 0.75 | HPGD (0.38) | HPGDHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3912982-A1 | NOVEL HYDROPHILIC LINKERS AND LIGAND-DRUG CONJUGATES THEREOF | Hangzhou Dac Biotech Co., Ltd (CN) | 2021-11-24 | — | — | EP | disclosed |
| EP-3271329-B1 | NOVEL HYDROPHILIC LINKERS AND LIGAND-DRUG CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO LTD (CN) | 2021-08-18 | — | — | EP | disclosed |
| US-10456479-B2 | Hydrophilic linkers and ligand-drug conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2019-10-29 | — | — | US | disclosed |
| US-20180110876-A1 | NOVEL HYDROPHILIC LINKERS AND LIGAND-DRUG CONJUGATES THEREOF | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2018-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10456479-B2 | Hydrophilic linkers and ligand-drug conjugates thereof | CD44, SELPLG, EPCAM | HPGD 1325/4885HTT 907/4885SMN1; SMN2 4329/4885 |
| US-20180110876-A1 | NOVEL HYDROPHILIC LINKERS AND LIGAND-DRUG CONJUGATES THEREOF | CD44, HACD3, HACD2 | HPGD 1722/4885HTT 1456/4885SMN1; SMN2 4269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.